XBIO · Xenetic Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $806.9K | - | $1.03M | $589.9K | $593.3K | - | $614.2K | $726.4K | $510.8K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $661.4K | - | $756.5K | $656.6K | $879.0K | - | $368.0K | $933.8K | $944.3K | - |
| SG&A | $647.6K | - | $815.2K | $657.8K | $656.6K | - | $745.7K | $1.13M | $834.9K | - |
| Total Operating Expenses | $1.31M | - | $1.57M | $1.31M | $1.54M | - | $1.11M | $2.06M | $1.78M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($502.1K) | - | ($544.7K) | ($724.4K) | ($942.4K) | - | ($499.5K) | ($1.34M) | ($1.27M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($456.4K) | - | ($509.9K) | ($688.7K) | ($903.1K) | - | ($436.7K) | ($1.27M) | ($1.20M) | - |
| EPS - Basic | ($0.20) | - | ($0.33) | ($0.45) | ($0.59) | - | ($0.28) | ($0.83) | ($0.78) | - |
| EPS - Diluted | ($0.20) | - | ($0.33) | ($0.45) | ($0.59) | - | ($0.28) | ($0.83) | ($0.78) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.35M | $7.88M | $4.12M | $4.78M | $5.16M | $6.17M | $6.84M | $7.30M | $7.82M | $8.98M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $558.8K | $258.1K | $578.3K | $346.8K | $240.3K | $283.6K | $243.3K | $283.6K | $210.5K | $240.8K |
| Current Assets | $7.60M | $8.05M | $5.07M | $5.35M | $5.48M | $6.59M | $7.03M | $8.01M | $8.38M | $9.59M |
| Total Assets | $7.91M | $8.36M | $5.07M | $5.35M | $5.79M | $6.90M | $8.05M | $9.03M | $9.39M | $10.61M |
| Current Liabilities | $958.2K | $968.0K | $1.11M | $903.4K | $667.9K | $894.3K | $1.01M | $1.59M | $716.5K | $809.6K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $958.2K | $968.0K | $1.11M | $903.4K | $667.9K | $894.3K | $1.01M | $1.59M | $716.5K | $809.6K |
| Stockholders' Equity | $6.95M | $7.40M | $3.96M | $4.45M | $5.12M | $6.01M | $7.04M | $7.45M | $8.68M | $9.80M |
| Retained Earnings | ($200.33M) | ($199.88M) | ($199.30M) | ($198.79M) | ($198.10M) | ($197.19M) | ($196.14M) | ($195.70M) | ($194.43M) | ($193.23M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($536.4K) | - | - | - | ($1.00M) | - | - | - | ($1.16M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -62.2% | - | -53.0% | -122.8% | -158.9% | - | -81.3% | -184.1% | -248.3% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -56.6% | - | -49.7% | -116.7% | -152.2% | - | -71.1% | -175.4% | -234.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 82.0% | - | 73.7% | 111.3% | 148.2% | - | 59.9% | 128.5% | 184.9% | - |
| SG&A / Revenue | 80.3% | - | 79.4% | 111.5% | 110.7% | - | 121.4% | 155.6% | 163.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.8% | - | -10.1% | -12.9% | -15.6% | - | -5.4% | -14.1% | -12.7% | - |
| Return on equity | -6.6% | - | -12.9% | -15.5% | -17.6% | - | -6.2% | -17.1% | -13.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.93 | 8.32 | 4.56 | 5.93 | 8.20 | 7.37 | 6.96 | 5.05 | 11.69 | 11.84 |
| Quick ratio | 7.93 | 8.32 | 4.56 | 5.93 | 8.20 | 7.37 | 6.96 | 5.05 | 11.69 | 11.84 |
| Cash ratio | 7.67 | 8.14 | 3.71 | 5.29 | 7.73 | 6.89 | 6.78 | 4.60 | 10.92 | 11.10 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.14 | 1.13 | 1.28 | 1.20 | 1.13 | 1.15 | 1.14 | 1.21 | 1.08 | 1.08 |
| Liabilities / Assets | 0.12 | 0.12 | 0.22 | 0.17 | 0.12 | 0.13 | 0.13 | 0.18 | 0.08 | 0.08 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | - | 0.20 | 0.11 | 0.10 | - | 0.08 | 0.08 | 0.05 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 36.0% | - | 67.2% | -18.8% | 16.1% | - | 0.5% | 11.6% | -15.7% | - |
| Revenue CAGR (3y) | 10.0% | - | 35.3% | 12.3% | 15.1% | - | 20.7% | 36.2% | 38.8% | - |
| Revenue CAGR (5y) | 33.4% | - | 54.7% | - | 59.9% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 46.7% | - | -9.1% | 45.8% | 25.7% | - | 56.4% | -11.6% | -38.6% | - |
| Net income growth (YoY) | 49.5% | - | -16.8% | 45.9% | 24.4% | - | 58.6% | -21.2% | -39.5% | - |
| EPS growth (YoY) | 66.1% | - | -17.9% | 45.8% | 24.4% | - | 59.4% | -20.3% | -550.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 35.7% | 23.1% | -43.8% | -40.2% | -41.0% | -38.7% | -35.4% | -37.3% | -32.5% | -28.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$1.16M totalRoyalty$1.16M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Xenetic Biosciences against the 5 most active filers in the same SIC group.